Cytokinetics (NASDAQ: CYTK) announced that CK-2017357, its fast skeletal muscle troponin activator, 
has received Fast Track designation from the FDA for the potential treatment of amyotrophic lateral sclerosis (ALS), also commonly known as Lou Gehrig's Disease.
- Cytokinetics anticipates that results from two recently completed Phase II clinical trials, designed to assess the safety and tolerability of CK-2017357 in patients with ALS, will be presented at the American Academy of Neurology 64th Annual Meeting in New Orleans, LA on April 25, 2012.
- Cytokinetics has met with the FDA's Division of Neurology Products and with the European Medicines Agency to discuss its progress in the development of CK-2017357 as a potential treatment for patients with ALS and the company's plans for its further development, including potential registration strategies.
- Cytokinetics is assessing options that may enable the initiation of a registration program for CK-2017357.
- Cytokinetics anticipates having additional interactions with U.S. and European regulatory authorities during 2012 to discuss the development of CK-2017357 as a potential treatment for patients with ALS, including potential registration strategies.
Daily Dose Conclusion: New treatments for ALS and competition could pressure cell therapy company Neuralstem (CUR).
